– USA, MD – Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced the appointments of Dr. June Almenoff (M.D., Ph.D.) and Mitchell Chan to its Board as Independent Directors, effective respectively November 10, 2021, and December 1, 2021, replacing Dr. Suzanne Bruhn and Philip Gutry.
“We are pleased to welcome both Dr. Almenoff and Mr. Chan to our Board. Their collective experience will be invaluable as we advance through several key inflection points and strategic priorities in the coming year and we look forward to their immediate contributions to the company’s success,” said CEO, Mike Cola.
About Dr. June Almenoff
June Almenoff M.D., Ph.D., is an accomplished biopharma executive with close to 25 years of leadership experience. She brings expertise in R&D, commercialization, and executive leadership to this role. Dr. Almenoff served as President and CMO of Furiex Pharmaceuticals, which was acquired by Actavis for $1.2 billion. Furiex developed eluxadoline, which was approved both in the United States and Europe. Before joining Furiex, Dr. Almenoff was at GlaxoSmithKline for 12 years, where she held various positions of increasing responsibility.
Dr. Almenoff is currently CMO at RedHill Biopharma Ltd, where she serves on the commercial executive team. She has deep expertise in many therapeutic and development areas having led or contributed to numerous submissions, product approvals, and launches. Dr. Almenoff is on the investment advisory board of the Harrington Discovery Institute, private venture philanthropy. She serves as a Board Director to Brainstorm Therapeutics Inc. and Tenax Therapeutics, Inc. She previously served as a Board Director to Tigenix, which was acquired by Takeda, Kurome Therapeutics, RDD Pharma (Chair), and Furiex Pharmaceuticals.
Dr. Almenoff received her B.A. cum laude from Smith College and graduated with AOA honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine. She completed post-graduate medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine. She is an adjunct professor at Duke, a Fellow of the American College of Physicians, and has authored over 60 publications.
About Mitchell Chan
Mitchell Chan has more than 15 years of finance experience in the life sciences industry. Mr. Chan was previously the CFO at Viela Bio, where he was instrumental in supporting the company through capital raises with leading global healthcare investors. While at Viela Bio, he successfully raised over $750 million including an initial public offering in 2019. In 2021, he also led a merger transaction whereby Viela Bio was acquired by Horizon Therapeutics for $3.1 billion. Before Viela Bio, Mr. Chan served as the Director of Investor Relations for AstraZeneca, North America. Mr. Chan also held several roles of increasing responsibility at Genentech-Roche including in BioOncology Commercial Finance, R&D Finance, and Mergers & Acquisitions.
Mr. Chan is the recipient of Executive Certifications from Stanford University, the University of California, and the University of Pennsylvania and earned his BSc in Biochemistry, MSc in Medical Biophysics, and MBA (Rotman School of Management) from the University of Toronto.
About Avalo Therapeutics
Avalo Therapeutics is a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. The Company has built a diverse portfolio of innovative therapies to deliver meaningful medical impact for patients in urgent need. The Company’s clinical candidates commonly have a proven mechanistic rationale, biomarkers, and/or an established proof-of-concept to expedite and increase the probability of success.
For more information: https://www.avalotx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.